FDA Green Light on Phase 3 for EB613, but Financing Gating Remains

What happened

Entera Bio received positive FDA feedback on the Phase 3 protocol for EB613, its oral osteoporosis tablet, which the company frames as clearing a major regulatory hurdle. However, the DeepValue report highlights that the company explicitly states it requires additional funding to commence Phase 3, and existing cash only supports operations through mid-Q3 2026. The stock sits near the report's attractive entry of $0.95, but the base case valuation of $1.35 assumes both FDA alignment and committed financing. The positive news reduces regulatory risk but does not address the capital overhang, as the ATM facility allows up to 30 million additional shares, which could dilute per-share value.

Implication

Investors should not chase the stock solely on the FDA news. The investment thesis requires two observable events: explicit FDA 'may proceed' (now likely received) and committed Phase 3 financing that extends runway beyond mid-Q3 2026. The base case valuation of $1.35 assumes both events occur; without financing, dilution risk remains high. Position sizing should reflect that the bull case ($2.20) depends on minimally dilutive capital, while the bear case ($0.75) reflects continued ATM usage and trial delays. Re-assess only after financing clarity.

Thesis delta

The regulatory hurdle for Phase 3 has been cleared, reducing part of the thesis risk, but the critical financing gap persists. The thesis shifts from 'wait for FDA feedback' to 'wait for committed funding,' as the company still needs capital to start enrollment. The overall rating remains WAIT until a financing deal sufficient to initiate Phase 3 is announced.